新诺威主营业务为食品添加剂和保健食品的研发、生产与销售，主要产品包括咖啡因类食品添加剂和保 健食品类产品。公司所属行业为食品制造业，涉及维生素、食品饮料等概念板块。 数据显示，新诺威8月22日主力资金净流入201.08万元，近五日主力资金净流出7008.94万元。 截至2025年8月22日收盘，新诺威股价报50.85元，较前一交易日上涨1.5%。当日成交量为61822手，成 交金额达3.13亿元。 风险提示：药物研发存在高投入、高风险、周期长等特点，短期内对公司业绩不会产生重大影响。 公司控股子公司石药集团巨石生物制药有限公司近日收到国家药品监督管理局核准签发的关于SYS6036 注射液的《药物临床试验批准通知书》。SYS6036注射液是一款肿瘤免疫治疗的人源化单克隆抗体药 物，预计将适用于治疗黑色素瘤、非小细胞肺癌、食管癌、头颈部鳞状细胞癌等多种肿瘤。 ...

（文章来源：证券日报） 证券日报网讯 8月22日晚间，新诺威发布公告称，公司控股子公司石药集团巨石生物制药有限公司于近 日收到国家药品监督管理局核准签发的关于SYS6036注射液的《药物临床试验批准通知书》，将于近期 开展临床试验。 ...

Core Viewpoint - The approval of SYS6036 injection by the National Medical Products Administration of China marks a significant advancement for the company in the field of tumor immunotherapy [1] Group 1: Product Development - SYS6036 is a humanized monoclonal antibody drug aimed at tumor immunotherapy, specifically targeting melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1] - The product has been submitted under the category of biological products for therapeutic use, specifically Class 3.3 [1] - The development of SYS6036 adheres to the research guidelines for biosimilars, indicating a structured approach to its clinical development [1] Group 2: Research Findings - Pharmaceutical and non-clinical research results demonstrate that SYS6036 shows high similarity in quality, safety, and efficacy compared to the reference drug, supporting the initiation of subsequent clinical studies [1]

Core Viewpoint - XinNuoWei (300765) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SYS6036 injection, a humanized monoclonal antibody drug for tumor immunotherapy [1] Group 1 - SYS6036 injection is classified as a Class 3.3 therapeutic biological product [1] - The drug is expected to be used for the treatment of multiple cancers, including melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1]